Daily Archives: Janeiro 10, 2022 | LinksMedicus Free Medical News & Perspectives

Early vaccine safety data for children ages 5–11 years old found that reactions such as fatigue and headaches were commonly reported following Pfizer-BioNTech #COVID19 vaccine. Everyone ages 5 years & older should get vaccinated as soon as possible. https://t.co/D66QgLRWni pic.twitter.com/8I48L5GmcG

— MMWR (@CDCMMWR) December 30, 2021

Estudo CDC | Uma estratégia de testar para ficar (permitindo que contatos próximos de infectados por COVID-19 permaneçam na escola) foi muito eficaz em evitar progressão da disseminação na escola e permitiu que as crianças continuassem em sala de aula como uma alternativa à quarentena domiciliar.

10 Jan, 2022 | 12:46h

Evaluation of Test to Stay Strategy on Secondary and Tertiary Transmission of SARS-CoV-2 in K–12 Schools — Lake County, Illinois, August 9–October 29, 2021 – CDC Morbidity and Mortality Weekly Report

Estudo CDC relacionado: Evaluation of a Test to Stay Strategy in Transitional Kindergarten Through Grade 12 Schools — Los Angeles County, California, August 16–October 31, 2021 – CDC Morbidity and Mortality Weekly Report

Diretrizes CDC relacionadas:

What You Should Know About COVID-19 Testing in Schools – Centers for Disease Control and Prevention

Science Brief: Transmission of SARS-CoV-2 in K-12 Schools and Early Care and Education Programs – Updated – Centers for Disease Control and Prevention

Comentário: ‘Test-to-stay’ works to keep students in school safely, CDC director says – CNN

Conteúdos relacionados:

Instead of quarantine for Covid-exposed students, some schools are trying test-to-stay.

Cluster RCT: Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission.

Kids are losing school days to quarantines. Here’s a way to keep them in classrooms – “Test-to-stay could dramatically reduce close contact quarantines”.

Opinion | Data from routine Covid testing can help schools stay open this year.

Comentário no Twitter

Although vaccination is the best way to protect against #COVID19 for those aged 5 and up, schools might consider Test to Stay strategy for allowing close contacts who are not fully vaccinated to remain in the classroom. Learn more in a new @CDCMMWR: https://t.co/3m64vomRDh. pic.twitter.com/AAENAdxJ1y

— CDC (@CDCgov) December 17, 2021

[Preprint] Risco de miocardite após vacinações sequenciais contra COVID-19 por idade e sexo.

10 Jan, 2022 | 12:43h

Risk of myocarditis following sequential COVID-19 vaccinations by age and sex – medRxiv

Comentário: An evaluation of the association between COVID vaccination and myocarditis in 42 million people aged 13 or older – News Medical

Nota: este estudo é uma análise atualizada de um estudo recente, publicado na revista Nature Medicine; ver abaixo:

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Diagnóstico de COVID-19: mudando de resposta à pandemia para o controle.

10 Jan, 2022 | 12:40h

Diagnostics for COVID-19: moving from pandemic response to control – The Lancet

Comentário no Twitter

Diagnostics—crucial during the #COVID19 pandemic.

A new Review discusses the 3 major methods for detection of SARS-CoV-2 infection & their evolution over time: moving from pandemic response to control.

Learn more 👉 https://t.co/6Him1H3VG7 pic.twitter.com/jt7yHkolCK

— The Lancet (@TheLancet) December 21, 2021

[Preprint] Estudo randomizado | Em adultos sintomáticos com mais de 18 anos e com teste positivo para SARS-CoV-2, o tratamento ambulatorial precoce com plasma convalescente com altos títulos de anticorpos reduziu significativamente as internações.

10 Jan, 2022 | 12:39h

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma – medRxiv

Comunicado de imprensa: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine

Comentário: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science

[Preprint] Entre indivíduos com infecção prévia pelo SARS-CoV-2 no Brasil, a efetividade da vacina contra internações ou morte após a vacinação completa foi de 81,3% para a CoronaVac, 89,9% para a AstraZeneca, 57,7% para a J&J e 89,7% para a Pfizer.

10 Jan, 2022 | 12:36h

Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among – medRxiv

Comentário de um dos autores no Twitter (fio – clique para saber mais)

Já tive COVID, devo me vacinar?

Sim, sem dúvida. Como já dizíamos, agora com dados. Mostramos (preprint) que o ganho em proteção é muito grande. Para hospitalizações/óbito, após 2a dose:

➡️ 89.7% Pfizer
➡️ 89.9% AstraZeneca
➡️ 81.3% CoronaVac

Vacine-sehttps://t.co/Gzcb3cjirX pic.twitter.com/TRET1VQqQE

— Otavio Ranzani (@otavio_ranzani) December 29, 2021

[Preprint] Estudo mostrou gravidade clínica reduzida em pacientes com Covid-19 admitidos em hospitais de Gauteng, na África do Sul, durante a 4ª onda da variante dominante Ômicron – “qualquer combinação de menor virulência, comorbidades, alta imunidade a partir de infecção prévia ou vacinação pode ser um fator contribuinte importante para essa apresentação clínica.”

10 Jan, 2022 | 12:34h

Clinical Severity of COVID-19 Patients Admitted to Hospitals in Gauteng, South Africa During the Omicron-Dominant Fourth Wave – SSRN/Preprints with The Lancet

Comentário: SARS-CoV-2 omicron variant may be less severe than the delta variant – News Medical

Em comparação com as ondas anteriores, a onda de Ômicron na África do Sul foi associada com menos internações e reduzidas gravidade e mortalidade.

10 Jan, 2022 | 12:30h

Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves – JAMA

OMS | 10 principais momentos de saúde global em 2021.

10 Jan, 2022 | 12:29h

10 key global health moments from 2021 – World Health Organization

Comentário no Twitter (fio – clique para saber mais)

10 key global health moments from 2021 https://t.co/QYt8jV9WWh pic.twitter.com/ZPoM3zFPzI

— World Health Organization (WHO) (@WHO) December 21, 2021

Arquivos do dia: Janeiro 10, 2022

Relatório CDC | Segurança da vacina contra COVID-19 em crianças de 5 a 11 anos de idade.